Open AccessRelapse predictability of topological signature on pretreatment planning CT images of stage I non‐small cell lung cancer patients before treatment with stereotactic ablative radiotherapy
Author(s) -
Kodama Takumi,
Arimura Hidetaka,
Shirakawa Yuko,
Ninomiya Kenta,
Yoshitake Tadamasa,
Shioyama Yoshiyuki
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14483
Subject(s) - sabr volatility model , medicine , stage (stratigraphy) , ablative case , lung cancer , radiation therapy , radiation treatment planning , oncology , radiology , volatility (finance) , paleontology , stochastic volatility , financial economics , economics , biology
Background This study aimed to explore the predictability of topological signatures linked to the locoregional relapse (LRR) and distant metastasis (DM) on pretreatment planning computed tomography images of stage I non‐small cell lung cancer (NSCLC) patients before treatment with stereotactic ablative radiotherapy (SABR). Methods We divided 125 primary stage I NSCLC patients (LRR: 34, DM: 22) into training ( n = 60) and test datasets ( n = 65), and the training dataset was augmented to 260 cases using a synthetic minority oversampling technique. The relapse predictabilities of the conventional wavelet‐based features (WF), topology‐based features [BF, Betti number (BN) map features; iBF, inverted BN map features], and their combined features (BWF, iBWF) were compared. The patients were stratified into high‐risk and low‐risk groups using the medians of the radiomics scores in the training dataset. Results For the LRR in the test, the iBF, iBWF, and WF showed statistically significant differences ( p < 0.05), and the highest nLPC was obtained for the iBF. For the DM in the test, the iBWF showed a significant difference and the highest nLPC. Conclusion The iBF indicated the potential of improving the LRR and DM prediction of stage I NSCLC patients prior to undergoing SABR.